Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer

Background: Accumulating evidence suggests that necroptosis, or programmed necrotic cell death, may play a significant role in cancer. We evaluated the expression of key molecules in necroptosis and their association with clinical features and prognosis in NSCLC. Methods: A total of 253 NSCLC patients (96 squamous cell carcinoma [SCC] cases and 157 adenocarcinoma [AC] cases) who underwent curative resection were included. Tumor tissues and corresponding normal tissues were investigated for relative mRNA expression levels of RIPKI , RIPK3, and MLKL. Difference in disease free survival (DFS) was analyzed according to the expression levels of these molecules in tumor tissues. Results: NSCLC tissues had significantly lower expression of RIPKI , RIPK3, and MLKL than normal tissues (P = 1 x 10(-4) , P = 8 x 10(-6) , and P = 4 x 10(-8) , respectively). In subgroup analysis, SCCs had significantly lower RIPKI, RIPK3, and MLKL expression (P = 5 x 10(-4) , P = 3 x 10(-15) , P = 1 x 10(-5) , respectively), and ACs had significantly lower RIPKI and MLKL expression (P = 0.01 and P = 6 x 10(-4) , respectively) than normal tissues. Low expression of RIPKI, RIPK3, and MLKL in tumors was associated with a worse DFS (HR = 1.71, P = 0.01; HR = 1.53, P = 0.04; and HR = 1.53, P = 0.04, respectively) in a multivariate analysis. In SCC, none of the RIPKI, RIPK3, and MLKL expression was significantly associated with DFS. However, in AC, low expression of RIPKI , RIPK3, and MLKL was significantly associated with worse DFS (HR = 1.67, P = 0.03; HR = 1.70, P = 0.03; and HR = 1.81, P = 0.02, respectively). Conclusions: Key regulatory genes in necroptosis, RIPKI, RIPK3, and MLKL, were downregulated in NSCLC, and their lower expression in NSCLC may be used to predict early recurrence after curative resection, especially in AC.